 Acute coronary syndromes ACS, which include unstable angina and non-ST-elevation non-STE myocardial infarction, represent a serious clinical condition affecting over 1,000,000 people in the US alone. The combined rate of death and myocardial infarction MI in ACS patients is 8-15 after one month, in spite of the best current therapy including use of low-molecular weight heparins, glycoprotein IIbIIIa GPIIbIIIa inhibitors, and an early invasive strategy. Given the high prevalence of the disorder, further improvements in the outcomes in these patients are very desirable. 